Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B

Ratings ESG MSCI

Ratings BioCryst Pharmaceuticals, Inc.: Strengths and Weaknesses

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Highlights: BioCryst Pharmaceuticals, Inc.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Historically, the company has been releasing figures that are above expectations.
Weaknesses: BioCryst Pharmaceuticals, Inc.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Rating Financials

BioCryst Pharmaceuticals, Inc. SectorUnited States

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

BioCryst Pharmaceuticals, Inc. SectorUnited States

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

BioCryst Pharmaceuticals, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

BioCryst Pharmaceuticals, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

BioCryst Pharmaceuticals, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
2.22B -
B
- -
70.88B
AAA
62.49B
A
26.34B
AAA
26.21B -
BBB
- -
24.13B - - - -
20.72B
A
15.36B
AA
14.46B
BB
14.24B - - - -
Average 27.7B
A
Weighted average by Cap.
A
  1. Stock Market
  2. Stocks
  3. BCRX Stock
  4. Ratings BioCryst Pharmaceuticals, Inc.
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!